2009
Predictors of Rapid HIV Testing Acceptance and Successful Nevirapine Administration in Zambian Labor Wards
Megazzini KM, Chintu N, Vermund SH, Redden DT, Krebs DW, Simwenda M, Tambatamba B, Sinkala M, Stringer JS. Predictors of Rapid HIV Testing Acceptance and Successful Nevirapine Administration in Zambian Labor Wards. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 52: 273-279. PMID: 19568175, DOI: 10.1097/qai.0b013e3181ab6e7c.Peer-Reviewed Original ResearchConceptsNevirapine administrationHIV testingHIV statusHIV testing acceptanceChild transmission servicesTime of admissionProvision of HIVResource-limited settingsSusceptible womenEligible womenPrimigravida womenHIV counselingCervical dilationLabour wardTesting acceptanceEligibility criteriaTesting ratesInert tabletsWomenHIVAdministrationCounselingPredictorsHoursStatus
2007
Influence of body mass index on pregnancy outcomes among HIV‐infected and HIV‐uninfected Zambian women
Banda Y, Chapman V, Goldenberg RL, H. B, Vermund SH, Stringer JS. Influence of body mass index on pregnancy outcomes among HIV‐infected and HIV‐uninfected Zambian women. Tropical Medicine And International Health 2007, 12: 856-861. PMID: 17596253, PMCID: PMC2570322, DOI: 10.1111/j.1365-3156.2007.01857.x.Peer-Reviewed Original ResearchConceptsBody mass indexPregnancy outcomesBirth weightInfant weightMass indexZambian womenBMI unitsLower body mass indexChild transmission ratePerinatal HIV transmissionPrevention of motherHIV viral loadInfant birth weightMean birth weightTransmission of HIVNevirapine administrationPrior stillbirthBMI quartilesCD4 countChild transmissionViral loadHIV transmissionMaternal parityUnivariate analysisClinical trials
2004
Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings
Stringer J, Sinkala M, Goldenberg RL, Kumwenda R, Acosta EP, Aldrovandi GM, Stout JP, Vermund SH. Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings. AIDS 2004, 18: 939-943. PMID: 15060442, PMCID: PMC2745979, DOI: 10.1097/00002030-200404090-00012.Peer-Reviewed Original ResearchConceptsChild HIV transmissionUnknown HIV serostatusHIV serostatusHIV transmissionPreliminary efficacyLabour wardHIV DNA polymerase chain reactionSingle-dose nevirapinePrevention of motherProspective cohort studyEvidence of infectionHigh-prevalence settingsWeeks of lifeNevirapine administrationNevirapine coverageChild transmissionCohort studyComparison cohortAdherence ratesPrevalence settingsPolymerase chain reactionCord bloodDNA polymerase chain reactionHIVInfant specimens
2000
Cost-Effective Use of Nevirapine to Prevent Vertical HIV Transmission in Sub-Saharan Africa
Stringer J, Rouse D, Vermund S, Goldenberg R, Sinkala M, Stinnett A. Cost-Effective Use of Nevirapine to Prevent Vertical HIV Transmission in Sub-Saharan Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 369-377. DOI: 10.1097/00042560-200008010-00012.Peer-Reviewed Original ResearchConceptsVertical HIV transmissionHIV transmissionPrenatal carePrevention strategiesEffects of NVPModest clinical efficacyOptimal prevention strategiesGreater health gainsDecision analysis modelNevirapine administrationNVP administrationPrenatal visitPreventive therapyStandard therapyClinical efficacySaharan AfricaMass therapyPrenatal strategiesClinical assessmentPrior enrollmentTherapyCost-effective useHealth gainsWomenSerostatusCost-Effective Use of Nevirapine to Prevent Vertical HIV Transmission in Sub-Saharan Africa
Stringer J, Rouse D, Vermund S, Goldenberg R, Sinkala M, Stinnett A. Cost-Effective Use of Nevirapine to Prevent Vertical HIV Transmission in Sub-Saharan Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 369-377. DOI: 10.1097/00126334-200008010-00010.Peer-Reviewed Original ResearchVertical HIV transmissionHIV transmissionPrenatal carePrevention strategiesEffects of NVPModest clinical efficacyOptimal prevention strategiesGreater health gainsDecision analysis modelNevirapine administrationNVP administrationPrenatal visitPreventive therapyStandard therapyClinical efficacySaharan AfricaMass therapyPrenatal strategiesClinical assessmentPrior enrollmentTherapyCost-effective useHealth gainsWomenSerostatusCost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa.
Stringer J, Rouse D, Vermund S, Goldenberg R, Sinkala M, Stinnett A. Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 369-77. PMID: 11015154, DOI: 10.1097/00126334-200008010-00012.Peer-Reviewed Original ResearchConceptsVertical HIV transmissionHIV transmissionPrenatal carePrevention strategiesEffects of NVPModest clinical efficacyOptimal prevention strategiesSaharan AfricaGreater health gainsDecision analysis modelNevirapine administrationNVP administrationPrenatal visitPreventive therapyStandard therapyClinical efficacyMass therapyPrenatal strategiesClinical assessmentPrior enrollmentTherapyCost-effective useHealth gainsWomenSerostatus